{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:37:15Z","timestamp":1785429435523,"version":"3.56.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The detection of biomarkers in blood or tumor tissue samples may affect the efficacy of targeted therapy in patients with non\u2013small cell lung cancer (NSCLC). The FoundationOne Liquid CDx (F1LCDx) and tissue FoundationOne CDx (F1CDx) companion diagnostic tests were approved by the US Food and Drug Administration to identify patients with BRAF V600E\u2013mutant metastatic NSCLC who may benefit from encorafenib combined with binimetinib. This clinical bridging study aimed to establish F1LCDx and F1CDx as companion diagnostics for the identification of patients with BRAF V600E\u2013mutant metastatic NSCLC and to determine concordance between these tests and clinical trial assays (CTA) in samples from patients enrolled in the phase II PHAROS trial. In samples with sufficient circulating tumor DNA (ctDNA; defined as tumor fraction \u22651%), F1LCDx testing revealed a positive percent agreement (PPA) of 83.3% (Wilson score two-sided 95% confidence interval, 68.1%\u201392.1%). F1CDx testing revealed a PPA of 93.2% (85%\u201397%), suggesting that F1CDx may robustly identify patients with BRAF V600E\u2013mutant NSCLC and complement F1LCDx testing in this population. The efficacy of encorafenib plus binimetinib in patients selected by F1LCDx or F1CDx was based on the objective response rate (ORR) by independent radiology review in the PHAROS trial. The estimated ORRs in the F1LCDx+\/CTA+ population were 60.4% versus 63.3% in the CTA+ population. Similarly, the estimated ORRs in the F1CDx+\/CTA+ population were 70.6% versus 64.1% in the CTA+ population. These findings suggest that both tests may be clinically useful in predicting the efficacy of encorafenib plus binimetinib in patients with metastatic NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This clinical bridging study assessed F1LCDx and tissue F1CDx companion diagnostic tests for identifying patients with BRAF V600E\u2013mutant metastatic NSCLC. Results support both tests in identifying patients and predicting an objective response in patients who may be eligible for treatment with encorafenib combined with binimetinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0102","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:32:04Z","timestamp":1783017124000},"page":"1814-1824","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Validation of Tissue and Liquid Companion Diagnostics for\n                    <i>BRAF<\/i>\n                    V600E Detection in Non\u2013Small Cell Lung Cancers from the PHAROS Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-4313","authenticated-orcid":false,"given":"Gregory J.","family":"Riely","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-1401","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Martini","sequence":"additional","affiliation":[{"name":"2Pfizer, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-5216","authenticated-orcid":false,"given":"Norberto","family":"Pantoja Galicia","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9897-2806","authenticated-orcid":false,"given":"Brian","family":"Tunquist","sequence":"additional","affiliation":[{"name":"4Pfizer, Boulder, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-7865","authenticated-orcid":false,"given":"Keith","family":"Wilner","sequence":"additional","affiliation":[{"name":"2Pfizer, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-5168","authenticated-orcid":false,"given":"Richard S.P.","family":"Huang","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-119X","authenticated-orcid":false,"given":"Cui","family":"Guo","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-263X","authenticated-orcid":false,"given":"Shibing","family":"Deng","sequence":"additional","affiliation":[{"name":"2Pfizer, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2300-3960","authenticated-orcid":false,"given":"Wei","family":"Meng","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3310-0837","authenticated-orcid":false,"given":"Jimmy","family":"Kiely","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7315","authenticated-orcid":false,"given":"Linda","family":"Zhou","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8528-3781","authenticated-orcid":false,"given":"David L.","family":"Smith","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-5285","authenticated-orcid":false,"given":"Mark","family":"Hartman","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5287-0064","authenticated-orcid":false,"given":"Chenming","family":"Cui","sequence":"additional","affiliation":[{"name":"3Foundation Medicine, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7627-9519","authenticated-orcid":false,"given":"Nada","family":"Rifi","sequence":"additional","affiliation":[{"name":"5Pfizer, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-3677","authenticated-orcid":false,"given":"Bruce E.","family":"Johnson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 6 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-6639","authenticated-orcid":false,"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 7 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"Suppl 1","key":"2026072910334329900_bib1","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.21037\/jtd.2018.11.85","article-title":"The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients","volume":"11","author":"Hofman","year":"2019","journal-title":"J Thorac Dis"},{"key":"2026072910334329900_bib2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/cas.12963","article-title":"Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure","volume":"107","author":"Kawamura","year":"2016","journal-title":"Cancer Sci"},{"key":"2026072910334329900_bib3","doi-asserted-by":"publisher","first-page":"LMT40","DOI":"10.2217\/lmt-2020-0022","article-title":"Biopsy frequency and complications among lung cancer patients in the United States","volume":"9","author":"Zhang","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"2026072910334329900_bib4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41416-022-01777-8","article-title":"Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?","volume":"127","author":"Bonanno","year":"2022","journal-title":"Br J Cancer"},{"key":"2026072910334329900_bib5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026072910334329900_bib6","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"2026072910334329900_bib7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/cyt.13295","article-title":"Circulating tumour DNA testing in metastatic breast cancer: integration with tissue testing","volume":"34","author":"Ranghiero","year":"2023","journal-title":"Cytopathology"},{"key":"2026072910334329900_bib8","doi-asserted-by":"publisher","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"2026072910334329900_bib9","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"key":"2026072910334329900_bib10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"2026072910334329900_bib11","doi-asserted-by":"publisher","first-page":"e2500181","DOI":"10.1200\/PO-25-00181","article-title":"Prospective multicenter study evaluating a combined circulating tumor DNA and circulating tumor RNA liquid biopsy in metastatic non-small cell lung cancer (LIQUIK)","volume":"9","author":"Samol","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026072910334329900_bib12","doi-asserted-by":"publisher","first-page":"e005344","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026072910334329900_bib13","volume-title":"Foundation Medicine, Inc. FDA approves FoundationOne\u00aeCDx and FoundationOne\u00aeLiquid CDx as companion diagnostics for Pfizer\u2019s BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) to identify patients with BRAF V600E alterations in metastatic NSCLC","year":"2023"},{"key":"2026072910334329900_bib14","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072910334329900_bib15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/10781552251322452","article-title":"BRAF inhibitors with or without MEK inhibitors in advanced BRAF-positive non-small cell lung cancer: a systematic review","volume":"31","author":"Saha","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"2026072910334329900_bib16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2022.09.008","article-title":"Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort","volume":"173","author":"Lim","year":"2022","journal-title":"Lung Cancer"},{"key":"2026072910334329900_bib17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"2026072910334329900_bib18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026072910334329900_bib19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1007\/s12325-024-02839-4","article-title":"A practical review of encorafenib and binimetinib therapy management in patients with BRAF V600E-mutant metastatic non-small cell lung cancer","volume":"41","author":"Baik","year":"2024","journal-title":"Adv Ther"},{"key":"2026072910334329900_bib20","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC-a brief report","volume":"20","author":"Riely","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026072910334329900_bib21","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO-25-02023","article-title":"Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer","volume":"43","author":"Johnson","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072910334329900_bib22","article-title":"FoundationOne\u00ae Liquid CDx","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"2026072910334329900_bib23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","article-title":"Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice","volume":"5","author":"Trevethan","year":"2017","journal-title":"Front Public Health"},{"key":"2026072910334329900_bib24","article-title":"Prevalence","volume-title":"StatPearls [Internet]","author":"Tenny","year":"2026"},{"key":"2026072910334329900_bib25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"2026072910334329900_bib26","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026072910334329900_bib27","doi-asserted-by":"publisher","first-page":"E748","DOI":"10.1073\/pnas.1320956111","article-title":"Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer","volume":"111","author":"Lin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026072910334329900_bib28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2015.15281","article-title":"Multiple imputation: a flexible tool for handling missing data","volume":"314","author":"Li","year":"2015","journal-title":"JAMA"},{"key":"2026072910334329900_bib29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"2026072910334329900_bib30","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026072910334329900_bib31","doi-asserted-by":"publisher","first-page":"e2200261","DOI":"10.1200\/po.22.00261","article-title":"Tumor fraction correlates with detection of actionable variants across &gt;23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026072910334329900_bib32","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/clinchem\/hvab176","article-title":"Circulating cell-free DNA yield and circulating-tumor DNA quantity from liquid biopsies of 12 139 cancer patients","volume":"67","author":"Huang","year":"2021","journal-title":"Clin Chem"},{"key":"2026072910334329900_bib33","article-title":"The evolution of liquid biopsy in cancer care","author":"Cavallo","year":"2021"},{"key":"2026072910334329900_bib34","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/diagnostics14090912","article-title":"Advancing evidence generation for circulating tumor DNA: lessons learned from a multi-assay study of baseline circulating tumor DNA levels across cancer types and stages","volume":"14","author":"McKelvey","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026072910334329900_bib35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/curroncol32030146","article-title":"Lung cancer: targeted therapy in 2025","volume":"32","author":"Bouchard","year":"2025","journal-title":"Curr Oncol"},{"key":"2026072910334329900_bib36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cancers17050853","article-title":"Oncogenic mutations and the tumor microenvironment: drivers of non-small cell lung cancer progression","volume":"17","author":"Mitrakas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026072910334329900_bib37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1021\/acs.jproteome.4c00773","article-title":"Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes","volume":"24","author":"Nicholas","year":"2025","journal-title":"J Proteome Res"},{"key":"2026072910334329900_bib38","doi-asserted-by":"publisher","first-page":"1611733","DOI":"10.3389\/pore.2024.1611733","article-title":"The rapidly changing field of predictive biomarkers of non-small cell lung cancer","volume":"30","author":"T\u00f3th","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"2026072910334329900_bib39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41571-025-01011-3","article-title":"Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials","volume":"22","author":"Ernst","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026072910334329900_bib40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0102\/3809989\/crc-26-0102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1814\/3817371\/crc-26-0102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1814\/3817371\/crc-26-0102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:33:51Z","timestamp":1785335631000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1814\/787172\/Clinical-Validation-of-Tissue-and-Liquid-Companion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0102","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33110905","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110929","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110868","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110935","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110947","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110959","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110890","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110941","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110862","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110884","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110953","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110878","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110866","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110938","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110869","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110908","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110956","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110902","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110881","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110863","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110932","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110893","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110944","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110865","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110887","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110950","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110875","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33110962","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8622940","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}